Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.

Autor: Miyahira AK; Science Department, Prostate Cancer Foundation, Santa Monica, California., Pienta KJ; Department of Urology, The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland., Babich JW; Department of Radiology, Weill Cornell Medicine, New York, New York., Bander NH; Laboratory of Urologic Oncology, Department of Urology and Meyer Cancer Center, Weill Cornell Medicine, New York, New York., Calais J; Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Choyke P; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Hofman MS; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia.; Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia., Larson SM; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Lin FI; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Morris MJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Pomper MG; Department of Urology, The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland., Sandhu S; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia., Scher HI; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York., Tagawa ST; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York., Williams S; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia.; Department of Radiation Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia., Soule HR; Science Department, Prostate Cancer Foundation, Santa Monica, California.
Jazyk: angličtina
Zdroj: The Prostate [Prostate] 2020 Nov; Vol. 80 (15), pp. 1273-1296. Date of Electronic Publication: 2020 Aug 31.
DOI: 10.1002/pros.24056
Abstrakt: Introduction: The Prostate Cancer Foundation (PCF) convened a PCF prostate-specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 November 2019, at Weill Cornell Medicine, New York, NY.
Methods: The meeting was attended by 22 basic, translational, and clinical researchers from around the globe, with expertise in PSMA biology, development and use of PSMA theranostics agents, and clinical trials. The goal of this meeting was to discuss the current state of knowledge, the most important biological and clinical questions, and critical next steps for the clinical development of PSMA positron emission tomography (PET) imaging agents and PSMA-targeted radionuclide agents for patients with prostate cancer.
Results: Several major topic areas were discussed including the biology of PSMA, the role of PSMA-targeted PET imaging in prostate cancer, the physics and performance of different PSMA-targeted PET imaging agents, the current state of clinical development of PSMA-targeted radionuclide therapy (RNT) agents, the role of dosimetry in PSMA RNT treatment planning, barriers and challenges in PSMA RNT clinical development, optimization of patient selection for PSMA RNT trials, and promising combination treatment approaches with PSMA RNT.
Discussion: This article summarizes the presentations from the meeting for the purpose of globally disseminating this knowledge to advance the use of PSMA-targeted theranostic agents for imaging and treatment of patients with prostate cancer.
(© 2020 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: